A.-R. Hanauske

869 total citations
43 papers, 702 citations indexed

About

A.-R. Hanauske is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A.-R. Hanauske has authored 43 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Molecular Biology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A.-R. Hanauske's work include Lung Cancer Treatments and Mutations (9 papers), Cancer therapeutics and mechanisms (7 papers) and Cancer Treatment and Pharmacology (7 papers). A.-R. Hanauske is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer therapeutics and mechanisms (7 papers) and Cancer Treatment and Pharmacology (7 papers). A.-R. Hanauske collaborates with scholars based in Germany, Netherlands and United Kingdom. A.-R. Hanauske's co-authors include H. Depenbrock, J. Wanders, José Jimeno, Robert Peter, Jaap Verweij, G. Catimel, Alan Anthoney, M. Roelvink, Chris Twelves and M. E. Scheulen and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

A.-R. Hanauske

43 papers receiving 678 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A.-R. Hanauske Germany 14 341 308 214 103 81 43 702
A.E.C. Korst Belgium 16 264 0.8× 292 0.9× 158 0.7× 89 0.9× 35 0.4× 20 681
Griswold Dp United States 14 496 1.5× 338 1.1× 187 0.9× 95 0.9× 58 0.7× 19 885
Yuji Shimamoto Japan 14 584 1.7× 346 1.1× 413 1.9× 77 0.7× 65 0.8× 19 947
Fumio Nakagawa Japan 20 682 2.0× 381 1.2× 299 1.4× 118 1.1× 78 1.0× 61 1.2k
Douglas Bootle Switzerland 13 582 1.7× 718 2.3× 304 1.4× 150 1.5× 86 1.1× 17 1.2k
Corbett Th 8 377 1.1× 267 0.9× 143 0.7× 50 0.5× 47 0.6× 8 652
David Taber United States 11 643 1.9× 445 1.4× 475 2.2× 280 2.7× 47 0.6× 28 1.2k
H. Depenbrock Germany 14 575 1.7× 239 0.8× 494 2.3× 148 1.4× 63 0.8× 33 935
Manish Monga United States 13 478 1.4× 582 1.9× 158 0.7× 66 0.6× 45 0.6× 37 1.0k
Hisanobu Niitani Japan 18 654 1.9× 358 1.2× 578 2.7× 55 0.5× 48 0.6× 65 1.1k

Countries citing papers authored by A.-R. Hanauske

Since Specialization
Citations

This map shows the geographic impact of A.-R. Hanauske's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.-R. Hanauske with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.-R. Hanauske more than expected).

Fields of papers citing papers by A.-R. Hanauske

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.-R. Hanauske. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.-R. Hanauske. The network helps show where A.-R. Hanauske may publish in the future.

Co-authorship network of co-authors of A.-R. Hanauske

This figure shows the co-authorship network connecting the top 25 collaborators of A.-R. Hanauske. A scholar is included among the top collaborators of A.-R. Hanauske based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.-R. Hanauske. A.-R. Hanauske is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ranson, Malcolm, Martin Reck, Alan Anthoney, et al.. (2007). 6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study. European Journal of Cancer Supplements. 5(4). 384–384. 2 indexed citations
2.
Hanauske, A.-R., Bart C. Kuenen, D. Thornton, et al.. (2006). Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 24(18_suppl). 2047–2047. 9 indexed citations
3.
Hanauske, A.-R., L. Goedhals, Hans Gelderblom, et al.. (2005). Pharmacokinetics (PK) of free and total paclitaxel after equal doses of paclitaxel injectable emulsion and paclitaxel injection. Journal of Clinical Oncology. 23(16_suppl). 2045–2045. 4 indexed citations
4.
Bolling, Claus, et al.. (2004). Pemetrexed/gemcitabine/cisplatin: Phase I trial in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3096–3096. 4 indexed citations
5.
Twelves, Chris, Klaas Hoekman, A. Bowman, et al.. (2003). Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. European Journal of Cancer. 39(13). 1842–1851. 75 indexed citations
6.
7.
Sessa, Cristiana, J. Wanders, M. Roelvink, et al.. (2000). Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG). Annals of Oncology. 11(2). 207–210. 16 indexed citations
8.
Gamucci, Teresa, Bernhard Heinrich, Jan H.M. Schellens, et al.. (2000). Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study. Annals of Oncology. 11(7). 793–797. 20 indexed citations
9.
Schöffski, Patrick, G. Catimel, A.S.T. Planting, et al.. (1999). Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 10(1). 119–122. 83 indexed citations
10.
Curé, H., P Souteyrand, Alain Ravaud, et al.. (1999). Results of a phase II trial with cystemustine at 90 mg/m2 as a first-or second-line treatment in advanced malignant melanoma. Melanoma Research. 9(6). 607–610. 9 indexed citations
11.
Thödtmann, R., Andreas Hüttmann, C. Manegold, et al.. (1998). Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Investigational New Drugs. 16(4). 319–324. 27 indexed citations
12.
Droz, J.P., A.-R. Hanauske, Jaap Verweij, et al.. (1998). Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. British Journal of Cancer. 77(1). 139–146. 13 indexed citations
13.
Depenbrock, H., Robert Peter, Bernhard K. Keppler, et al.. (1997). Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells. European Journal of Cancer. 33(14). 2404–2410. 46 indexed citations
14.
Judson, Ian, T. Cerny, Ron Epelbaum, et al.. (1997). Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Annals of Oncology. 8(6). 604–606. 46 indexed citations
15.
Hanauske, A.-R. & Lutz Edler. (1996). New Clinical Trial Designs for Phase I Studies in Hematology and Oncology: Principles and Practice of the Continual Reassessment Model. Oncology Research and Treatment. 19(5). 404–409. 2 indexed citations
16.
Hanauske, A.-R.. (1996). The development of new chemotherapeutic agents. Anti-Cancer Drugs. 7. 29–32. 5 indexed citations
17.
Mross, K., Andreas Hüttmann, Kenneth D. Herbst, et al.. (1996). Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611 A study by the AIO groups PHASE-I and APOH. Cancer Chemotherapy and Pharmacology. 38(3). 217–224. 16 indexed citations
18.
Hanauske, A.-R., et al.. (1995). Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. European Journal of Cancer. 31(10). 1677–1681. 11 indexed citations
19.
Depenbrock, H., Mathias Freund, Georg Erdmann, et al.. (1990). Effects of cytokines on in vitro colony formation of primary human tumour specimens. European Journal of Cancer and Clinical Oncology. 26(10). 1070–1074. 28 indexed citations
20.
Sarosy, Gisele, A.-R. Hanauske, Jerry L. Phillips, et al.. (1990). Phase I Trial and Biochemical Evaluation of Tiazofurin Administered on a Weekly Schedule. PubMed. 6(1). 51–61. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A.E.C. Korst Breakdown of academic impact, for papers by Griswold Dp Breakdown of academic impact, for papers by Yuji Shimamoto Breakdown of academic impact, for papers by Fumio Nakagawa Breakdown of academic impact, for papers by Douglas Bootle Breakdown of academic impact, for papers by Corbett Th Breakdown of academic impact, for papers by David Taber Breakdown of academic impact, for papers by H. Depenbrock Breakdown of academic impact, for papers by Manish Monga Breakdown of academic impact, for papers by Hisanobu Niitani
Rankless by CCL
2026